Over 40,000 participants from around the world, representatives of the largest pharmaceutical companies, innovators, decision-makers, and scientists – this is what CPHI Frankfurt 2025 (October 28–30 this year), the largest and most influential event in the pharmaceutical industry in Europe, promises to be. This group would not be complete without Łukasiewicz –Industrial Chemistry Institute (Łukasiewicz – ICI) – the leader of Polish pharmaceutical independence and creator of innovative solutions in the field of APIs (Active Pharmaceutical Ingredients). Our presence at the fair is endorsed by the slogan European API Excellence, which captures the essence of what we do: we develop and manufacture active substances that save the health and lives of millions of patients every year.
In recent years, we have been consistently rebuilding Poland’s potential in API production, combining over 70 years of experience in the field of pharmacy with state-of-the-art research and production infrastructure. In 2024 alone, we produced over 253 million doses of active substances, which translated into treatment for over 2.4 million patients. We operate on the basis of GMP and CEP certificates, our APIs are registered in over 60 countries, including Japan, and our portfolio includes both well-known molecules and completely new substances ready for commercialization. We currently have 10 active substances in production, another 10 are ready to be launched, and 19 APIs – developed entirely by our scientists – are awaiting market launch. Our products include cladribine, used in the treatment of multiple sclerosis, as well as vitamin D analogues (including Tacalcitol and Calcifediol), for which we are one of the few manufacturers in the world with European CEP certification.
Participation in CPHI is not only an opportunity to present our achievements, but also to discuss the future of pharmacy. We believe that in the face of global crises – pandemics, supply chain instability, growing dependence on Asia – Europe needs its own API expertise more than ever. Łukasiewicz – ICI’s response to this challenge is the ongoing construction of the Mościcki Campus – one of the largest R&D investments in Central and Eastern Europe in the field of pharmacy and biotechnology. The PLN 240 million project, co-financed by the National Recovery Plan, includes three modern research centers and seven laboratories—including a dedicated API Manufacturing Technology Center—prepared to carry out projects at TRL 9 technological readiness level.
“API is not a medicine. It is life in a pill,” says Wojciech Maszewski, Director of the Pharmaceutical Products Department at Łukasiewicz – ICI. “At CPHI, we will show that Poland has everything it needs to be a pillar of drug safety in Europe: knowledge, technology, and production capacity. I cordially invite you to meet our team in Frankfurt—let’s talk about a shared future that begins right here.”
You can find us at CPHI Frankfurt 2025, Messe Frankfurt, booth 3.0K72T.
written by M.S.
